3Tsushima T, Hironaka S, Boku N, et al. Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer [J]. Gastric Cancer, 2010,13(4) : 245-250.
5Miller A B, Hoogstraten B, Staquet M, et al. Reporting re- suits of cancer treatment [J]. Cancer, 1981,47 ( 1 ) : 207.
6Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in adavanced gastric cancer? [ J ]. Lancet Oncol, 2009,10 (9) : 903.
7M Malet-Martino, R Martino. Clinical studies of three oral prodrugs of 5-Fluorouracil( Capecitabine, UFT, S-1 ) : a re- view [J]. The oncologist, 2002,7 ( 4 ) : 288.
8Koizumi W. S-1 plus cisplatin vel - us S-1 alone for first line treatment of advanced gastric cancer. ( SPIRITS tri- al) :a phasem trial[J]. Lancet Oncol,2008,9(3) :215.
9Koizumi W, Kurihara M, Nakano S, et al. Phase 11 study of S-I ,a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Stud- y Group[ J]. Oncology,2000,58 (3) : 191.
10Ajani JA, Rodriquez W, Bodoky G, et al. Muhlcenter phase llI comparison of cisplatin/S-1 with cisplatin/infu-sional fluoronracil in advanced gastric or gastroesophageal adeno- carcinoma study : the FLAGS trial [ J ]. J Clin Oncol, 2010, 28(9) :1547.
